Blog

Davoceticept as monotherapy and in combination with pembrolizumab in advanced solid tumors

Photo taken from acgtfoundation.org

Aug 6, 2024, 10:23

Davoceticept as monotherapy and in combination with pembrolizumab in advanced solid tumors

Journal for ImmunoTherapy of Cancer made the following post on X:

“New JITC article: Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2).”

Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)

Authors: Diwakar Davar, Ludimila Cavalcante, Nehal Lakhani, Justin Moser, Michael Millward, Meredith McKean, Mark Voskoboynik, Rachel E. Sanborn, Jaspreet S. Grewal, Ajita Narayan, Amita Patnaik, Justin F. Gainor, Mario Sznol, Amanda Enstrom, Lori Blanchfield, Heidi LeBlanc, Heather Thomas, Michael J. Chisamore, Stanford L. Peng, Allison Naumovski.

Source: Journal for ImmunoTherapy of Cancer/X

Ajita Narayan Allison Naumovski Amanda Enstrom Amita Patnaik cancer Diwakar Davar Heather Thomas Heidi LeBlanc Jaspreet S. Grewal Justin F. Gainor Justin Moser Lori Blanchfield Ludimila Cavalcante Mario Sznol Mark Voskoboynik Meredith McKean Michael J. Chisamore Michael Millward Nehal Lakhani OncoDaily Oncology Rachel E. Sanborn Stanford L. Peng

Immunotherapy for Melanoma: Types, Success Rate, Side Effects & More

Tom Green and Testicular Cancer: How He Went Against, How He Survived, and More

Steven O'Day: At the Forefront of Immunotherapy

Dennis Slamon was honored with the 2024 Szent-Györgyi Prize for Progress in Cancer Research

Pfizer is partnering with Patrick Dempsey in support of the American Cancer Society initiative 'Change the Odds'

Special Coverage